Adherex gets regulatory clearance for phase 2 weekly dosing schedule of ADH-1

By Lisa Kerner

Erie, Pa., March 28 - Adherex Technologies Inc. said it has received regulatory clearance from Health Canada to convert the dosing schedule of its phase 2 study of single agent ADH-1 to once every week from once every three weeks.

The phase 2 single-agent trial is designed to evaluate the anti-tumor activity and tolerability of repeated doses of ADH-1 in patients with lung, esophageal, adrenocortical, renal and hepatocellular cancers whose tumors express the molecular target N-cadherin, according to a company news release.

Adherex anticipates enrolling up to 100 patients at sites in the United States and Canada.

The company said it expects the trial to be completed in the second half of 2006.

"Based on our experience from our North American and European centers, this more dose dense, weekly dosing schedule of ADH-1 has been well tolerated and is preferable from a pharmacology standpoint," chairman and chief executive officer William P. Peters said in the release.

Adherex is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. The company is located in Research Triangle Park, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.